Lexeo Therapeutics, Inc.LXEOEarnings & Financial Report
Nasdaq
LXEO Q3 2022 Key Financial Metrics
Revenue
$531.0K
Gross Profit
N/A
Operating Profit
$-17.5M
Net Profit
$-17.1M
Gross Margin
N/A
Operating Margin
-3292.3%
Net Margin
-3211.9%
YoY Growth
N/A
EPS
$-10.38
Financial Flow
Lexeo Therapeutics, Inc. Q3 2022 Financial Summary
Lexeo Therapeutics, Inc. reported revenue of $531.0K for Q3 2022, with a net profit of $-17.1M (-3211.9% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $531.0K |
|---|---|
| Net Profit | $-17.1M |
| Gross Margin | N/A |
| Operating Margin | -3292.3% |
| Report Period | Q3 2022 |
Income Statement
| Q3 2022 | |
|---|---|
| Revenue | $531000 |
| YoY Growth | N/A |
Balance Sheet
| Q3 2022 | |
|---|---|
| Assets | N/A |
| Liabilities | N/A |
| Equity | $-99.0M |
Cash Flow
No data available for this period